Literature DB >> 23183425

Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.

M Sugita1, A Kalota, A M Gewirtz, M Carroll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183425      PMCID： PMC3987859          DOI： 10.1038/leu.2012.310

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling.

Authors:  M Tanaka; K Kirito; Y Kashii; M Uchida; T Watanabe; H Endo; T Endoh; K Sawada; K Ozawa; N Komatsu
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

2.  Quantitative expression of thrombopoietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia.

Authors:  A Takeshita; K Shinjo; M Izumi; P Ling; S Nakamura; K Naito; K Ohnishi; R Ohno
Journal:  Br J Haematol       Date:  1998-02       Impact factor: 6.998

3.  Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia.

Authors:  Francis Corazza; Christophe Hermans; Stéphanie D'Hondt; Alina Ferster; Alain Kentos; Yves Benoît; Eric Sariban
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

4.  Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Ekaterina Gibiansky; Jianping Zhang; Daphne Williams; Zhao Wang; Daniele Ouellet
Journal:  J Clin Pharmacol       Date:  2010-07-27       Impact factor: 3.126

5.  The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.

Authors:  M Sattler; M A Durstin; D A Frank; K Okuda; K Kaushansky; R Salgia; J D Griffin
Journal:  Exp Hematol       Date:  1995-08       Impact factor: 3.084

6.  Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3.

Authors:  C M Bacon; P J Tortolani; A Shimosaka; R C Rees; D L Longo; J J O'Shea
Journal:  FEBS Lett       Date:  1995-08-14       Impact factor: 4.124

7.  Thrombopoietin induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in a human thrombopoietin-dependent cell line.

Authors:  M Yamada; N Komatsu; K Okada; T Kato; H Miyazaki; Y Miura
Journal:  Biochem Biophys Res Commun       Date:  1995-12-05       Impact factor: 3.575

8.  Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro.

Authors:  Y Ezumi; H Takayama; M Okuma
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

9.  Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation.

Authors:  A L Gurney; S C Wong; W J Henzel; F J de Sauvage
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2.

Authors:  P J Tortolani; J A Johnston; C M Bacon; D W McVicar; A Shimosaka; D Linnekin; D L Longo; J J O'Shea
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113
View more
  7 in total

Review 1.  From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.

Authors:  Harinder Gill; Raymond S M Wong; Yok-Lam Kwong
Journal:  Ther Adv Hematol       Date:  2017-02-01

Review 2.  Eltrombopag in aplastic anemia.

Authors:  Ronan Desmond; Danielle M Townsley; Cynthia Dunbar; Neal S Young
Journal:  Semin Hematol       Date:  2014-10-31       Impact factor: 3.851

Review 3.  Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Authors:  W Li; K Morrone; S Kambhampati; B Will; U Steidl; A Verma
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

4.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Authors:  Michael Dickinson; Honar Cherif; Pierre Fenaux; Moshe Mittelman; Amit Verma; Maria Socorro O Portella; Paul Burgess; Pedro Marques Ramos; Jeea Choi; Uwe Platzbecker
Journal:  Blood       Date:  2018-10-10       Impact factor: 22.113

5.  c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.

Authors:  Christopher D Nishimura; Daniel A Brenner; Malini Mukherjee; Rachel A Hirsch; Leah Ott; Meng-Fen Wu; Hao Liu; Olga Dakhova; Jordan S Orange; Malcolm K Brenner; Charles Y Lin; Caroline Arber
Journal:  Blood       Date:  2017-10-27       Impact factor: 22.113

6.  Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival.

Authors:  Anna Kalota; Mary A Selak; Laura A Garcia-Cid; Martin Carroll
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

7.  Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Authors:  Vincent Jachiet; Guillaume Moulis; Jérome Hadjadj; Julie Seguier; Kamel Laribi; Nicolas Schleinitz; Norbert Vey; Karim Sacre; Bertrand Godeau; Odile Beyne-Rauzy; Romain Bouvet; Jonathan Broner; Natacha Brun; Thibault Comont; Clément Gaudin; Olivier Lambotte; Lenaïg Le Clech; Pierre Peterlin; Frédérique Roy-Peaud; Clémentine Salvado; Mathilde Versini; Françoise Isnard; Jean Emmanuel Kahn; Delphine Gobert; Lionel Adès; Pierre Fenaux; Olivier Fain; Arsène Mekinian
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.